Clinical data | |
---|---|
Other names | BTRX-140; CYM-53093; NMRA-140 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C25H32FN5O2 |
Molar mass | 453.562 g·mol−1 |
3D model (JSmol) | |
| |
|
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is an opioid antagonist medication which is under development for the treatment of depression.[1][2][3] It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder.[1][2][3] As of February 2020, BTRX-335140 is in phase 2 clinical trials for this indication.[2]
See also
References
- 1 2 "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.
- 1 2 3 "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
- 1 2 Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.